Basic Cardiovascular Sciences 2019 Scientific Sessions

July 29–August 1, 2019
Westin Boston Waterfront | Boston, Massachusetts

Registration Information
Registration for BCVS 2019 opens March 5, 2019


See Registration Rates and Housing Rates
Abstract Submission
Abstract & Awards submission opens January 9, 2019.


About this Meeting

The 14th annual BCVS 2018 Scientific Sessions has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.

The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.

In addition, the symposium will be of great value to scientists and executives of pharmaceutical companies and biotechnology firms who are in the cardiovascular space.

Target Audience

  • Basic cardiovascular scientists
  • Molecular/cellular biologists
  • Physiologists
  • Translational investigators
  • Clinical trialists
  • Practicing cardiologists
  • Cardiovascular nurses and pharmacists

Learning Objectives

At the conclusion of the conference, participants will be able to:
  1. Discuss advances in the underlying mechanisms that contribute to pathological cardiac remodeling and development of targeted therapeutic strategies to improve outcomes for patients with CVD.
  2. Evaluate the most recent evidence on the pathophysiological mechanisms underlying myocardial perfusion injury, supporting the use of cardioprotective strategies, including advances in oxidative stress-activated mechanisms in CVD pathophysiology.
  3. Discuss recent advances in understanding the complex interplay between signal transduction cascades in modulating apoptotic and functional pathways (mitochondrial, ion channels, metabolism) to identify novel drug targets and preserve functional cardiac myocytes.
  1. Describe current research exploring the integrated role of novel "omics" technologies and "big data" analytics that may allow for precision medicine and may improve patient outcomes by examining more holistically the pathophysiological mechanisms underlying cardiovascular function.
  2. Discuss the importance of state-of-the-art clinically relevant reprogrammed human cellular and large animal model systems, including the challenges to bridge the gap between basic science and clinical application of these modalities for improving translational research and outcomes in patients with CVD.
  3. Discuss challenges and issues arising regarding the pursuit of cardiovascular research, including future research directions, issues of responsibility in research and the move towards translation into clinical practice.
  4. Describe recent and emerging advances into the genetic and molecular mechanisms driving cardiomyopathy and heart failure that are guiding the development of interventions such as targeted gene therapy and regenerative stem cell therapy.